Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 80.4%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 145,807 shares, a growth of 80.4% from the June 30th total of 80,824 shares. Based on an average daily volume of 139,949 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.9% of the company’s shares are sold short.

Analysts Set New Price Targets

Several research firms have weighed in on ALLR. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Ascendiant Capital Markets upped their target price on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Price Performance

Allarity Therapeutics stock traded down $0.01 during mid-day trading on Friday, reaching $1.22. 20,700 shares of the stock traded hands, compared to its average volume of 168,892. The stock has a market capitalization of $19.33 million, a PE ratio of -1.68 and a beta of 0.53. Allarity Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.35. The business’s 50-day moving average is $1.38 and its 200-day moving average is $1.25.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts anticipate that Allarity Therapeutics will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALLR. Jane Street Group LLC purchased a new stake in Allarity Therapeutics in the 2nd quarter worth approximately $27,000. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics in the fourth quarter worth about $36,000. Geode Capital Management LLC boosted its stake in Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after buying an additional 16,729 shares during the last quarter. Capital Advisors Inc. OK bought a new stake in Allarity Therapeutics in the 4th quarter worth approximately $108,000. Finally, DRW Securities LLC purchased a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $133,000. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.